Adalimumab


Generic Medicine Info
Special Precautions
Patient w/ pre-existing or recent onset central or peripheral nervous system demyelinating disorders, heart failure or decreased left ventricular function; at risk of hepatitis B virus (HBV) infection. Reactivation and new onset of TB infection. Patient who travelled to or resided in regions where TB is endemic. Elderly. Pregnancy and lactation. Monitoring Parameters Perform tuberculin skin test and HBV screening prior to treatment. Monitor for signs and symptoms of infection prior to, during and following treatment.
Adverse Reactions
Upper resp tract infection, pulmonary and extrapulmonary (e.g. disseminated) TB, nasopharyngitis, sinusitis, headache, pyrexia, musculoskeletal pain, CVA, pulmonary embolism, DVT, alopecia, inj site reactions (itching, erythema, haemorrhage, pain or swelling), hepatobiliary disorders, liver failure, sarcoidosis, Merkel cell carcinoma, new or worsening psoriasis (all sub-types e.g. pustular and palmoplantar). Rarely, pancytopenia, aplastic anaemia, central and peripheral demyelinating events, lupus and related conditions, Stevens-Johnson syndrome.
Potentially Fatal: Sepsis, opportunistic infections, TB, HBV reactivation, other malignancies (e.g. leukaemia, lymphoma, hepatosplenic T-cell lymphoma), haematological, neurological and autoimmune reactions, anaphylaxis, angioneurotic oedema.
Drug Interactions
Increased risk of serious infections w/ other biologic disease-modifying antirheumatic drugs (e.g. abatacept, anakinra), rituximab. May increase immunosuppressant effect w/ tocilizumab, live vaccines.
ATC Classification
L04AB04 - adalimumab ; Belongs to the class of tumor necrosis factor alpha (TNF-a) inhibitors. Used as immunosuppressants.
Disclaimer: This information is independently developed by CIMS based on adalimumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in